Hancock Whitney’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $634K | Sell |
1,276
-65
| -5% | -$28.8K | 0.01% | 522 |
|
|
2026
Q1 | $574K | Buy |
1,341
+15
| +1% | +$6.99K | 0.01% | 538 |
|
|
2025
Q4 | $601K | Sell |
1,326
-13
| -1% | -$5.6K | 0.01% | 516 |
|
|
2025
Q3 | $524K | Sell |
1,339
-23
| -2% | -$9.61K | 0.01% | 556 |
|
|
2025
Q2 | $606K | Buy |
1,362
+19
| +1% | +$8.76K | 0.01% | 523 |
|
|
2025
Q1 | $651K | Sell |
1,343
-184
| -12% | -$85.7K | 0.02% | 391 |
|
|
2024
Q4 | $615K | Sell |
1,527
-1,181
| -44% | -$547K | 0.02% | 399 |
|
|
2024
Q3 | $1.26M | Sell |
2,708
-79
| -3% | -$37.9K | 0.04% | 276 |
|
|
2024
Q2 | $1.31M | Sell |
2,787
-5
| -0.2% | -$2.17K | 0.04% | 256 |
|
|
2024
Q1 | $1.17M | Buy |
2,792
+101
| +4% | +$42.7K | 0.04% | 278 |
|
|
2023
Q4 | $1.09M | Sell |
2,691
-93
| -3% | -$34.4K | 0.04% | 297 |
|
|
2023
Q3 | $968K | Buy |
2,784
+33
| +1% | +$11.5K | 0.04% | 306 |
|
|
2023
Q2 | $968K | Buy |
2,751
+208
| +8% | +$70.1K | 0.04% | 318 |
|
|
2023
Q1 | $801K | Buy |
2,543
+725
| +40% | +$217K | 0.03% | 336 |
|
|
2022
Q4 | $525K | Buy |
1,818
+2
| +0.1% | +$610 | 0.02% | 423 |
|
|
2022
Q3 | $526K | Buy |
1,816
+18
| +1% | +$5.18K | 0.02% | 406 |
|
|
2022
Q2 | $507K | Sell |
1,798
-290
| -14% | -$77.6K | 0.02% | 418 |
|
|
2022
Q1 | $545K | Buy |
2,088
+101
| +5% | +$24K | 0.02% | 440 |
|
|
2021
Q4 | $436K | Buy |
1,987
+24
| +1% | +$4.67K | 0.01% | 509 |
|
|
2021
Q3 | $356K | Buy |
1,963
+24
| +1% | +$4.69K | 0.01% | 542 |
|
|
2021
Q2 | $391K | Sell |
1,939
-113
| -6% | -$23.6K | 0.01% | 617 |
|
|
2021
Q1 | $441K | Sell |
2,052
-1,753
| -46% | -$385K | 0.02% | 576 |
|
|
2020
Q4 | $899K | Sell |
3,805
-35
| -0.9% | -$8.03K | 0.03% | 402 |
|
|
2020
Q3 | $1.04M | Sell |
3,840
-440
| -10% | -$121K | 0.04% | 360 |
|
|
2020
Q2 | $1.24M | Sell |
4,280
-55
| -1% | -$14.9K | 0.05% | 333 |
|
|
2020
Q1 | $1.03M | Buy |
4,335
+135
| +3% | +$31K | 0.04% | 359 |
|
|
2019
Q4 | $920K | Sell |
4,200
-201
| -5% | -$40.7K | 0.03% | 455 |
|
|
2019
Q3 | $746K | Sell |
4,401
-134
| -3% | -$23.7K | 0.02% | 499 |
|
|
2019
Q2 | $832K | Sell |
4,535
-51
| -1% | -$8.92K | 0.03% | 500 |
|
|
2019
Q1 | $844K | Buy |
4,586
+35
| +0.8% | +$6.46K | 0.03% | 506 |
|
|
2018
Q4 | $754K | Buy |
4,551
+1,935
| +74% | +$335K | 0.03% | 475 |
|
|
2018
Q3 | $504K | Buy |
+2,616
| New | +$466K | 0.01% | 640 |
|
Other funds holding VRTX
Hancock Whitney's VRTX Position: Q2 2026 in Review
Hancock Whitney reduced its Vertex Pharmaceuticals (VRTX) stake by 4.8% in Q2 2026, selling an estimated $28.8K and leaving 1,276 shares worth $634K. The position accounts for 0.01% of the portfolio, ranked #522.
Hancock Whitney first reported a position in VRTX in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.31M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Hancock Whitney held 1,276 shares of Vertex Pharmaceuticals worth $634K as of Q2 2026.
- Hancock Whitney sold 65 Vertex Pharmaceuticals shares in Q2 2026, an estimated $28.8K.
- Vertex Pharmaceuticals made up 0.01% of Hancock Whitney's portfolio in Q2 2026, its #522 holding.
- Hancock Whitney first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Hancock Whitney's Vertex Pharmaceuticals position peaked at $1.31M in Q2 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.